Question to the Department of Health and Social Care:

To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 17 February (HL13177), whether an intervention under the Health Service Medical Supplies (Costs) Act 2017 has taken place to control the cost of Liothyronine (T3); and if not, why not.

No such intervention has taken place. Several marketing authorisations have been granted for liothyronine since 2016 and the reimbursement price has been reducing as a direct response to more competition in the market.